Serum pleiotrophin levels are elevated in multiple myeloma patients and correlate with disease status

British Journal of Haematology

Volumn 133, Issue 5, 2006, Pages 526-529

  Yeh, Howard S ^a   Chen, Haiming ^a   Manyak, Steven J ^a   Swift, Regina A ^a   Campbell, Richard A ^a   Wang, Cathy ^a   Li, Mingjie ^a   Lee, Hee Jin ^a   Waterman, Gabriel ^a   Gordon, Melinda S ^a   Ma, Jonathan ^b   Bonavida, Benjamin ^c   Berenson, James R ^a  

^a INSTITUTE FOR MYELOMA AND BONE CANCER RESEARCH   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Angiogenesis; Biomarker; Multiple myeloma; Pleiotrophin; Prognostic factor

Indexed keywords

ANTIBODY; BIOLOGICAL MARKER; PLEIOTROPHIN;

ADULT; AGED; ARTICLE; CANCER PATIENT; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE COURSE; FEMALE; HEMATOLOGIC MALIGNANCY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SOLID TUMOR; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CARRIER PROTEINS; CYTOKINES; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PARAPROTEINEMIAS; PROGNOSIS;

EID: 33646239174     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2006.06052.x     Document Type: Article

References (12)

1. Blade J. Samson D. Reece D. Apperley J. Bjorkstrand B. Gahrton G. Gertz M. Giralt S. Jagannath S. Vesole D. 1998 Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. British Journal of Haematology 102 1115 1123.
2. Campbell R.A. Chen H. Lee H. Yeh H.S. Gordon M.S. Bonavida B. Pang S. Said J. Berenson J.R. 2005 Blocking pleiotrophin activity inhibits multiple myeloma cell growth in vitro and in a severe combined immunodeficient (SCID)-hu murine model of human myeloma. Blood 106 37a.
3. Chen H. Campbell R.A. Wang C. Li M. Lee H. Yeh H.S. Gui D. Gordon M.S. Said J. Bonavida B. Berenson J.R. 2005 Transdifferentiation of monocytes into endothelial cell by pleiotrophin. Blood 106 117a.
4. Czubayko F. Riegel A.T. Wellstein A. 1994 Ribozyme-targeting elucidates a direct role of pleiotrophin in tumor growth. Journal of Biological Chemistry 269 21358 21363.
5. Hatjiharissi E. Terpos E. Papaioannou M. Hatjileontis C. Kaloutsi V. Galaktidou G. Gerotziafas G. Christakis J. Zervas K. 2004 The combination of intermediate doses of thalidomide and dexamethasone reduces bone marrow micro-vessel density but not serum levels of angiogenic cytokines in patients with refractory/relapsed multiple myeloma. Hematological Oncology 22 159 168.
6. Kadomatsu K. Muramatsu T. 2004 Midkine and pleiotrophin in neural development and cancer. Cancer Letters 204 127 143.
7. Li G. Bunn J.R. Mushipe M.T. He Q. Chen X. 2005 Effects of pleiotrophin (PTN) over-expression on mouse long bone development, fracture healing and bone repair. Calcified Tissue International 76 299 306.
8. Meng K. Rodriguez-Pena A. Dimitrov T. Chen W. Yamin M. Noda M. Deuel T.F. 2000 Pleiotrophin signals increased tyrosine phosphorylation of beta beta-catenin through inactivation of the intrinsic catalytic activity of the receptor-type protein tyrosine phosphatase beta/zeta. Proceedings of the National Academy of Sciences of the United States of America 97 2603 2608.
9. Rauvala H. 1989 An 18-kd heparin-binding protein of developing brain that is distinct from fibroblast growth factors. EMBO Journal 8 2933 2941.
10. Soulie P. Heroult M. Bernard-Pierrot I. Caruelle D. Oglobine J. Barritault D. Courty J. 2004 Correlation of elevated plasma levels of two structurally related growth factors, heparin affin regulatory peptide and midkine, in advanced solid tumor patients. Cancer Detection and Prevention 28 319 324.
11. Souttou B. Juhl H. Hackenbruck J. Rockseisen M. Klomp H.J. Raulais D. Vigny M. Wellstein A. 1998 Relationship between serum concentrations of the growth factor pleiotrophin and pleiotrophin-positive tumors. Journal of the National Cancer Institute 90 1468 1473.
12. Wu H. Barusevicius A. Babb J. Klein-Szanto A. Godwin A. Elenitsas R. Gelfand J.M. Lessin S. Seykora J.T. 2005 Pleiotrophin expression correlates with melanocytic tumor progression and metastatic potential. Journal of Cutaneous Pathology 32 125 130.